As part of our commitment to accelerate your drug development program, we’ve condensed our reporting timeline to nine weeks for GLP-IND-enabling studies (up to three months in duration without peer review, 11 weeks for studies with peer review). This accelerated, 9-week timeline will enable us to deliver full IND programs within 26 or 27 weeks for small and large molecule programs, respectively.
A week may not seem like a long time in your overall drug development program, but it could make all the difference for patients who are depending on your research.
Accelerating timelines for your program is critical to get potentially life-saving treatments into the hands of patients faster; therefore, it’s crucial to choose a partner that can deliver you actionable data and reports quickly and accurately.
Additionally, by using a modernized, default report template, you’ll receive a high-quality report faster, enabling you to make rapid decisions or adjust the course of your program as necessary.
We will be expanding this new reporting model for all study types by early 2021.
Don’t wait another day to get your program off and running – let’s achieve your objectives together, faster.
IND Gantt Chart Builder
This interactive tool is meant to provide you with an estimated timeline to help you better plan your IND program.